Sunday, September 24

Main Hall

14:00 - 16:50

S-1    IATDMCT-JSTDM Joint Symposium: Expansion and Evolution of TDM and CT

S-1-1 Recollections: 1st CJSTDM & 1st ICTDM
Kazuhiko Tanaka (The first Congress Chair of ICTDM, Japan)

S-1-2 History of IATDMCT
Steven How-Yan Wong (The first President of IATDMCT, Wake Forest School of Medicine, USA)

S-1-3 Liaison between IATDMCT and Members
Denise Anne McKeown (IATDMCT Communication Committee, Msci, UK)

S-1-4 Overview of Clinical Toxicology
Gwendolyn Appell McMillin (University of Utah and ARUP Laboratories, USA)

S-1-5 The role of the laboratory in optimizing anti-infective therapies in critically ill patients
Pierre Wallemacq (Cliniques universitaires St Luc, Brussels, Belgium)

S-1-6 Improving clinical outcome using TDM
Teun van Gelder (Erasmus Medical Center Rotterdam, The Netherlands)

S-1-7 Expansion and Evolution of TDM and CT
Yusuke Tanigawara (15th Congress Chair, Keio University, Japan)

17:00 - 18:00

Opening Ceremony

Welcome Address
Yusuke Tanigawara (15th Congress Chair)

Presidential Address
Loralie J. Langman (IATDMCT President, Mayo Clinic, USA)

Awards Ceremonies
● Irving Sunshine Award for Outstanding Contributions to Clinical Toxicology
● C.E. Pippenger Award for Outstanding Contributions to Therapeutic Drug Monitoring
● Victor Armstrong Young Investigators’ Award
● Patsalos Prize for the best TDM manuscript published in Therapeutic Drug Monitoring

Annex Hall

18:00 - 19:30

IATDMCT Opening Reception
Monday, September 25

Main Hall

8:40 - 9:30
PL-1  Plenary Lecture 1
Mass spectrometry for research and clinical implementation of TDM&CT
Hans H. Maurer (Saarland University, Germany)

9:30 - 10:00
AL-1  Irving Sunshine Award Lecture

10:00 - 10:30  Coffee Break

10:30 - 12:00
S-2  TDM for the management of cancer therapy
S-2-1  Exposure-Response of chemotherapeutic agents
Etienne Chatelut (Institut Universitaire du Cancer de Toulouse, France)
S-2-2  Exposure-response and pharmacogenomics of tyrosine kinase inhibitors
Tomohiro Terada (Shiga University of Medical Science Hospital)
S-2-3  Optimization of CML therapy using TDM
Naoto Takahashi (Akita University, Japan)

13:30 - 14:30
O25-1  General Oral Session

14:30 - 15:00  Coffee Break

15:00 - 17:00
S-3  Biomarkers and TDM of Immunosuppressive Drugs
S-3-1  Biomarkers in Solid Organ Transplantation: Prospects and Challenges
Eberhard Wieland (Klinikum Stuttgart, Germany)
S-3-2  Clinical implementation of pharmacogenomics in kidney transplantation
Laure Elens (Catholic University of Louvain, Belgium)
S-3-3  Usefulness pharmacogenetic information in liver transplantation
Mercè Brunet (Hospital Clinic of Barcelona, Barcelona University, Spain)

Room D

10:30 - 12:00
S-4  TDM for multi-drug resistant organisms
S-4-1  TDM of daptomycin
TBA
S-4-2  Therapeutic drug monitoring of beta-lactam antibiotics
Menino Osbert Cotta (The University of Queensland, Australia)
S-4-3  Selected papers from general abstracts
13:30 - 14:30  O25-2 General Oral Session

14:30 - 15:00  Coffee Break

15:00 - 17:00  S-5 IATDMCT-JSTDM YS Joint Symposium 2017

S-5-1 PK and TDM of monoclonal antibodies for inflammatory bowel diseases
Sophie Berends (Academic Medical Center Amsterdam, The Netherlands)

S-5-2 Ultra-sensitive quantification of drugs and endogenous substances in human plasma using UPLC-MS/MS
Yosuke Suzuki (Oita University Hospital, Japan)

S-5-3 Bench-to-bedside research for the dermatological side effects induced by multiple tyrosine kinase inhibitors
Kazuhiro Yamamoto (Kobe University Hospital, Japan)

S-5-4 Therapeutic Drug Monitoring of Antiretrovirals: Applications in Management and Prevention
Mark Marzinke (Johns Hopkins University School of Medicine, USA)

Room E

10:30 - 12:00  S-6 TDM in Asia

S-6-1 TDM in Japan
Toshiyuki Sakaeda (President of JSTDM)

S-6-2 TDM in China
TBA

S-6-3 TBA

13:30 - 14:30  O25-3 General Oral Session

14:30 - 15:00  Coffee Break

15:00 - 17:00  S-7 Herbal Medicines: Toxicity, Interactions and Interferences in TDM

S-7-1 An overview of herbal remedies and their toxicity
Vanessa Steenkamp (University of Pretoria, South Africa)

S-7-2 TBA
Kiyoyuki Kitaichi (Gifu Pharmaceutical University, Japan)

S-7-3 Clinically important drug-herb interactions
Amitava Dasgupta (University of Texas-Houston Medical School at Houston, USA)

S-7-4 Interferences of herbal medicines in therapeutic drug monitoring
Thomas Y.K. Chan (Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong)
Room C1

10:30 - 12:00
O25-4 General Oral Session

13:30 - 14:30
O25-5 General Oral Session

14:30 - 15:00 Coffee Break

15:00 - 17:00
O25-6 General Oral Session

Room Swan

7:30 - 8:30
Roundtable discussion (ticket required)

Annex Hall
Poster & Exhibition

8:00 - 10:00 Poster Pin Up

9:00 - 16:00 Exhibition

10:00 - 12:00 Poster Viewing

10:00 - 10:30 Coffee Break

12:00 - 13:30 Poster Presentation
Lunch will be served.

13:30 - 16:00 Poster Viewing

14:30 - 15:00 Coffee Break

16:00 - 17:00 Poster Removal

17:00 - 18:30 Wine & Cheese Reception (Japanese style)
Tuesday, September 26

Main Hall

8:40 - 9:30
PL-2 Plenary Lecture 2
Why Use TDM and Dashboards for Monoclonal Antibodies?
The Promise of Individualized Therapy
Diane Renee Mould (Projections Research Inc., USA)

9:30 - 10:00
AL-2 C.E. Pippenger Award Lecture

10:00 - 10:30 Coffee Break

10:30 - 12:00
S-8 Pharmacometric approach on anti-infective medications
S-8-1 Dosing software to optimize antimicrobial therapy based on TDM
Franch Saint-Marcoux (University Hospital of Limoges, France)
S-8-2 Model-based voriconazole dosing in pediatric patients
Michael Noel Neely (Children's Hospital Los Angeles, University of Southern California, USA)
S-8-3 Dose Optimization of Anti-infective Agents - On Earth and in Space
Hartmut Derendorf (University of Florida, USA)

13:00 - 14:30 Annual General Meeting

14:30 - 15:00 Coffee Break

15:00 - 17:00
S-9 Young Scientist Symposium
S-9-1 Model based dosage optimization for pediatric patients
Tomoyuki Mizuno (Cincinnati Children's Hospital Medical Center, USA)
S-9-2 TDM improves the efficacy of cyclosporine A in aplastic anemia patients
Wangjun Qin (China-Japan Friendship Hospital, China)
S-9-3 Pharmacogenomics in Clinical Practice
Daiki Hira (Ritsumeikan University, Japan)
S-9-4 Re-establishment of target concentrations of immunosuppressive drugs using PKPD modeling
Brenda de Winter (Erasmus Medical Center, the Netherlands)
Room D

10:30 - 12:00
S-10  Progress of TDM for hematopoietic stem cell transplantation

S-10-1  Relevance of TDM to clinical outcomes with busulfan
         Jennifer Helen Martin (University of Newcastle, Australia)

S-10-2  Selected papers from general abstracts

13:30 - 14:30
Japanese Session (presented in Japanese language)

14:30 - 15:00  Coffee Break

15:00 - 17:00
S-11  Drug exposure during pregnancy and lactation

S-11-1  Trends in drug use during pregnancy; what can happen to the neonate?
         Birgit C.P. Koch (Erasmus MC, The Netherlands)

S-11-2  Biological specimens and approaches to testing designed to identify drug-exposed newborns
         Gwendolyn Appell McMillin (University of Utah and ARUP Laboratories, USA)

S-11-3  Neonatal drug exposure via lactation
         Shinya Ito (The Hospital for Sick Children, University of Toronto, Canada)

S-11-4  Use of iPS cells for the study of placental drug transport
         Kenji Ikeda (Osaka Ohtani University, Japan)

Room E

10:30 - 12:00
S-12  TDM for central nervous system drugs

S-12-1  TDM for a new class of anti-epileptic drugs
         Ikuko Yano (Kobe University Hospital, Japan)

S-12-2  Selected papers from general abstracts

14:30 - 15:00  Coffee Break

15:00 - 17:00
S-13  Debate session: Generics

S-13-1  What are the issues?
         Teun van Gelder (Erasmus Medical Center Rotterdam, The Netherlands)

S-13-2  The most different generics of tacrolimus are bioequivalent to each other and brand in kidney and liver transplant patients: A randomized, controlled trial
         Uwe Christians (University of Colorado, USA)
S-13-3 Evaluating transplant donor and recipient pharmacogenetics and its Impact on tacrolimus and metabolite pharmacokinetics in bioequivalence studies
Alexander Andhony Vinks (Cincinnati Children’s Hospital Medical Center, USA)

S-13-4 Generic immunosuppression in kidney transplantation; Japanese perspectives
Yoshihiko Watarai (Nagoya Second Red Cross Hospital, Japan)

Room C1

10:30 - 12:00
O26-1 General Oral Session

14:30 - 15:00 Coffee Break

15:00 - 17:00
O26-2 General Oral Session

Room Swan

7:30 - 8:30
Roundtable discussion (ticket required)

Annex Hall Poster & Exhibition

9:00 - 10:00 Poster Pin Up

9:00 - 17:00 Exhibition

10:00 - 10:30 Coffee Break

10:00 - 12:00 Poster Viewing

12:00 - 13:30 Poster Presentation
Lunch will be served.

13:30 - 16:00 Poster Viewing

14:30 - 15:00 Coffee Break

16:00 - 17:00 Poster Removal

Grand Prince Hotel Kyoto
Prince Hall (B2F)

19:00 - 23:00 Congress Dinner and Party
Wednesday, September 27

Main Hall

8:40 - 9:30
PL-3 Plenary Lecture 3
Circulating cell-free DNA as a new tool for personalized pharmacotherapy
Michael Oellerich (University Medicine Göttingen (UMG), Germany)

9:30 - 10:00
AL-3 Victor Armstrong Young Investigator Award Lecture

10:00 - 10:30 Coffee Break

10:30 - 12:00
S-14 Dried blood spot analysis: Are we ready for implementation?
S-14-1 Analytical perspective on developing a DBS assay for daily routine
TBA
S-14-2 Dried blood spot analysis: Are we ready for implementation?
Christophe Stove (Ghent University, Belgium)
S-14-3 Selected papers from general abstracts

13:30 - 13:45
AL-4 Patsalos Award Lecture

13:45 - 15:30
S-15 Applying TDM to HIV and TB therapy
S-15-1 Role of TDM in anti-retroviral therapy
Dario Cattaneo (Unit of Clinical Pharmacology– Luigi Sacco University Hospital, Italy)
S-15-2 Optimal HIV medications in pediatric patients
Natella Yurievna Rakhmanina (Children’s National/George Washington University, USA)
S-15-3 TDM of Anti-Tuberculosis Medications
Charles Arthur Peloquin (University of Florida, USA)

15:30 - 16:00 Coffee Break

16:00 - 17:00
Closing Ceremony
Presidential Lecture
Teun van Gelder (New President, IATDMCT)

Awards Presentations
• Best Poster Awards
• Best Oral presentation Awards
• Best Young Scientist oral presentation and Best Young Scientist poster prizes
Closing Remark
Yusuke Tanigawara (15th Congress Chair)

IATDMCT Flag Transfer

Invitation to the 16th Congress in Brisbane, Australia
Ross Norris and Andrew McLachlan (16th Co-Chairs)

Room D

10:30 - 12:00  
S-16  TDM of 5-FU

S-16-1  Management of 5-FU treatment using Therapeutic Drug Monitoring (TDM)
Edward Chu (University of Pittsburgh Cancer Institute, USA)

S-16-2  Selected papers from general abstracts

13:30 - 15:30
S-17  Assay and screening for drugs in clinical and forensic toxicology

S-17-1  Comprehensive Toxicology Screening in Clinical and Post Mortem Toxicology
Eric J.F. Franssen (OLVG Hospital, The Netherlands)

S-17-2  Alternative matrices for detection of drugs of abuse
Marilyn A. Huestis (NMS Labs, Inc., USA)

S-17-3  Advances of mass spectrometry for targeted and untargeted drug screening
Kara L. Lynch (UCSF, San Francisco, USA)

S-17-4  Cutting-edge mass spectrometric screening methods for new psychoactive substances
Kei Zaitsu (Nagoya University Graduate School of Medicine, Japan)

15:30 - 16:00  Coffee Break

Room E

10:30 - 12:00
S-18  TDM for cardiovascular and endocrine diseases

S-18-1  Reappraisal of TDM in Pharmacogenomic Generation
Hirotoshi Echizen (Meiji Pharmaceutical University, Japan)

S-18-2  TDM of cardiovascular drugs
Tsuyoshi Shiga (Tokyo Women’s Medical University, Japan)

S-18-3  Selected papers from general abstracts

13:30 - 15:30
S-19  Assessing human exposure to environmental pollutants

S-19-1  A new Scientific Committee on Environmental Health and Toxicology at IATDMCT. Scope and goals
Nicolas Venisse (Centre Hospitalier Universitaire de Poitiers, France)
S-19-2 Distribution of Pharmaceuticals in Clinical Wastewater from Medical Institutions and Development of Advanced Water Treatment Systems
Takashi Azuma (Graduate School of Pharmaceutical Sciences, Osaka University of Pharmaceutical Science, Japan)

S-19-3 Optimising human biomonitoring targets for environmental contaminants based on in vitro metabolism results - a case study of flame retardants
Nele Van den Eede (University of Antwerp/Ziekenhuis Netwerk Antwerpen, Belgium)

S-19-4 Physiologically based pharmacokinetic modeling as tool for the interpretation of biomonitoring data in the exposure assessment of environmental contaminants
Sami Haddad (Université de Montréal, Canada)

15:30 - 16:00 Coffee Break

Room C1

10:30 - 12:00
O27-1 General Oral Session

13:30 - 15:30
O27-2 General Oral Session

15:30 - 16:00 Coffee Break

Room Swan

7:30 - 8:30
Roundtable discussion (ticket required)

Annex Hall Poster & Exhibition

9:00 - 10:00 Poster Pin Up

9:00 - 15:30 Exhibition

10:00 - 12:00 Poster Viewing

10:00 - 10:30 Coffee Break

12:00 - 13:30 Poster Presentation
Lunch will be served.

13:30 - 15:30 Poster Viewing

15:30 - 16:00 Coffee Break

15:30 - 16:00 Poster Removal
Thursday, September 28
Post Congress Symposium
“Guidelines and Consensus Documents for TDM”

Room D

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:40 - 8:45</td>
<td>Opening Remark</td>
</tr>
<tr>
<td></td>
<td>Yusuke Tanigawara (Chair of the 15th IATDMCT Congress, Keio University, Japan)</td>
</tr>
<tr>
<td>8:45 - 9:15</td>
<td>Consensus Document on TDM of Everolimus</td>
</tr>
<tr>
<td></td>
<td>Maria Shipkova (Immunosuppressive Drugs Scientific Committee of the IATDMCT, Klinikum Stuttgart, Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin, Germany)</td>
</tr>
<tr>
<td>9:15 - 9:45</td>
<td>Guidelines on Therapeutic Drug Monitoring of Immunosuppressive Drugs Used in Organ Transplantation</td>
</tr>
<tr>
<td></td>
<td>Satohiro Masuda (Japanese Society of Therapeutic Drug Monitoring (JSTDM), Kyushu University Hospital, Japan)</td>
</tr>
<tr>
<td>9:45 - 10:15</td>
<td>Analytical methods of Measurement for Immunosuppressive Drug Concentrations</td>
</tr>
<tr>
<td></td>
<td>TBA (Immunosuppressive Drugs Scientific Committee of the IATDMCT)</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td>Break</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Dried blood spot (DBS) sampling and analysis guideline</td>
</tr>
<tr>
<td></td>
<td>Christophe Stove (Alternative Sampling Strategies Committee of the IATDMCT Laboratory of Toxicology, Ghent University, Belgium)</td>
</tr>
<tr>
<td>11:15 - 11:45</td>
<td>Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs</td>
</tr>
<tr>
<td></td>
<td>Tsuyoshi Shiga (Japanese Society of Therapeutic Drug Monitoring (JSTDM), Tokyo Women's Medical University, Japan)</td>
</tr>
<tr>
<td>11:45 - 13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Therapeutic Drug Monitoring of 5-Fluorouracil: An Approach Whose Time Has Come</td>
</tr>
<tr>
<td></td>
<td>Edward Chu (TDM in Oncology Scientific Committee of the IATDMCT, University of Pittsburgh Cancer Institute, USA)</td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Busulfan TDM: Current consensus and discrepancy</td>
</tr>
<tr>
<td></td>
<td>Erik van Maarseveen (TDM in Oncology Scientific Committee of the IATDMCT, University Medical Center Utrecht, The Netherlands)</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Guidelines for Therapeutic Drug Monitoring of Imatinib</td>
</tr>
<tr>
<td></td>
<td>William Alex Clarke (TDM in Oncology Scientific Committee of the IATDMCT, Johns Hopkins University School of Medicine, USA)</td>
</tr>
</tbody>
</table>
14:30 - 15:00  Break

15:00 - 15:30  Draft guidance for linezolid TDM
Gauri Rao (Anti-Infective Drugs Committee of the IATDMCT, University at North Carolina, USA)

15:30 - 16:00  Guidelines for Therapeutic Drug Monitoring of Antiepileptic Drugs
Toshiaki Sendo (Japanese Society of Therapeutic Drug Monitoring (JSTDM), Okayama University Hospital, Japan)

16:00 - 16:15  Closing Remark
Satohiro Masuda (Secretary of the 15th IATDMCT Congress, Kyushu University Hospital, Japan)